Mink Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MiNK Therapeutics reported increased net losses and a going concern warning in its 2025 annual report, while highlighting promising clinical progress for its lead iNKT cell therapy, agenT-797, in oncology and pulmonary diseases.
NASDAQ
10-K: MiNK Therapeutics Reports 2024 Results, Highlights Clinical Progress and Strategic Collaborations
MiNK Therapeutics details its 2024 financial results and provides an update on its clinical development programs, including agenT-797 and engineered iNKT cell therapies, along with strategic collaborations aimed at advancing cancer treatments.
NASDAQ
MiNK Therapeutics has obtained a convertible promissory note of up to $5 million from Agenus, while also filing its annual 10-K report detailing its financial status and clinical progress.